Veronvy

Provider Profile Name: Veronvy
Website: veronvy.com
Provider Type: Oral GLP-1 vendor
FDA Warning Letter: December 10, 2024
Registered Address: 3407 Felosa Drive, Rancho Dominguez, CA 90220
Public Contact Emails: service@obaskinec.com, service@Veronvy.com, service@herbaccouspf.com

Operating Details

Based on the public FDA record, Veronvy sold oral GLP-1-style products directly through its website rather than through a licensed-prescriber-plus-pharmacy telehealth workflow. The FDA reviewed veronvy.com in October 2024 and found that the site offered “Elily Veronvy” and “Elily Veronvy 40+” for sale in the United States. The warning letter does not describe a standard medical intake, physician-guided prescribing model, or regulated pharmacy fulfillment process comparable to legitimate GLP-1 telehealth providers.

Unlike platforms that connect patients with licensed clinicians, verify candidacy, and dispense medication through named 503A or 503B pharmacies, Veronvy’s public record centers on direct online sales claims. That distinction matters because the core issue here is not merely aggressive marketing or fuzzy wording. FDA classified the products themselves as unapproved new drugs and misbranded drugs under federal law.

About the Company

Very little trustworthy public company information exists beyond FDA enforcement documents and scattered web traces. The strongest verified source is FDA’s warning letter dated December 10, 2024, addressed simply to Veronvy at its Rancho Dominguez, California address. In that letter, FDA said the company’s website offered “Elily Veronvy” and “Elily Veronvy 40+” to U.S. consumers and concluded that these products were being marketed as drugs for human use.

What makes Veronvy somewhat different from the research-peptide vendors in this directory is that it was not framed around “semaglutide powder for research” or “lab use only” in the same way as Xcel, Swiss Chems, or Summit. Instead, Veronvy was marketing oral GLP-1 products directly as weight-loss solutions and, according to FDA, even implied that one product had been approved by the agency. FDA’s own December 17, 2024 roundup highlighted Veronvy separately and described it as offering unapproved and misbranded oral GLP-1 products, including one that claimed to be approved by FDA.

That is an important distinction because it places Veronvy closer to a deceptive consumer-facing wellness or supplement-style storefront than to either a legitimate clinic or a peptide vendor hiding behind a “research use only” disclaimer. The lack of transparent ownership, named prescribing clinicians, or licensed pharmacy disclosures adds to that concern.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Approach

Veronvy’s public-facing approach, as captured by FDA, centered on marketing oral drops for weight loss using GLP-1 language familiar to consumers who know Ozempic and Wegovy. The FDA warning letter quotes the website making claims that users lost up to 52 pounds in 3 months during clinical trials, that the product had been approved by the Food and Drug Administration, and that it worked through “The Science of GLP-1” by suppressing appetite, slowing gastric emptying, and accelerating metabolism.

Those are not neutral supplement claims. They are direct therapeutic drug claims. FDA concluded that these representations established the products’ intended use as drugs and that no approved drug applications were in effect for them. That is the central reason this company belongs in the “unapproved vendor” category rather than the telehealth provider category.

A broader industry piece discussing GLP-1 marketing also singled out Veronvy as the one supplement-like GLP-1 warning letter in late 2024, reinforcing that regulators viewed the company as selling products intended to affect the structure or function of the body in ways that trigger drug regulation.

GLP-1 Offerings and Weight Loss Services

The two publicly documented products were:

• Elily Veronvy
• Elily Veronvy 40+

FDA described these as oral GLP-1 products sold in the United States. The site promoted them for weight loss and metabolic effects, using language associated with medically supervised GLP-1 therapies. But there is no reliable public indication that Veronvy provided:

• licensed provider prescribing,
• medical screening,
• named compounding pharmacy fulfillment,
• dosage titration oversight,
• or ongoing clinical management.

This is the core safety difference between Veronvy and the real telehealth platforms in your directory. A legitimate GLP-1 clinic may still have flaws — unclear pricing, subscription problems, or weak customer service — but it still operates inside a medical structure. Veronvy’s documented model, by contrast, was selling oral GLP-1 products online with claims of FDA approval and clinical weight-loss effects without the transparent medical framework that should surround this class of medication.

Pricing — and What Reviewers Say

There is no reliable current pricing from the live site. Because the storefront is unstable or redirects away from its original commercial pages, and because the FDA warning letter is the strongest available public source, any pricing statement would be speculative. That is especially true for a company whose regulatory status is the defining issue.

There is also no meaningful independent review based on Trustpilot or Google that would support a credible “what reviewers say” section. In practice, this means prospective users cannot review the usual evidence points — shipping reliability, refund disputes, dosing consistency, side effects support, or customer service quality — through mainstream consumer-review platforms.

Reviews from Trustpilot and Google

No substantial independent Trustpilot or Google review pool was found for Veronvy. Search results around the brand are dominated by FDA records, warning-letter coverage, and low-trust affiliate or advertorial-style pages rather than a real patient-feedback trail. That absence is not a minor issue. For regulated medical services, a lack of provider identity, pharmacy transparency, and third-party review history makes independent verification much harder.

Compounding Pharmacies Used

No compounding pharmacy partners were publicly named in the FDA warning letter or in the public sources reviewed here. There is no clear public disclosure of a licensed 503A or 503B partner pharmacy associated with Veronvy’s products. That is a major red flag in the GLP-1 category, where the identity and status of the dispensing pharmacy is one of the most important pieces of information a patient can verify independently.

Note: The FDA issued a warning letter on December 10, 2024 after determining that Elily Veronvy and Elily Veronvy 40+ were unapproved and misbranded oral GLP-1 products being marketed in the United States. FDA specifically objected to claims that the products were FDA-approved and supported major clinical weight loss.

Veronvy is best understood as an online oral GLP-1 seller that drew direct FDA enforcement — not as a physician-led obesity medicine clinic. There is no meaningful public review trail, no disclosed pharmacy partner, and no verified evidence of a legitimate telehealth prescribing infrastructure. Patients seeking semaglutide or tirzepatide for weight management should use a licensed healthcare provider and a regulated pharmacy pathway rather than a storefront with this kind of enforcement history. FDA warned that failure to correct the cited violations could lead to further legal action, including seizure or injunction.